The data gathered in this study will allow healthcare providers “to have reliable data and enable discussion with caregivers of people with [Dravet syndrome] about the expected outcomes” of these medications, the team wrote.
The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in people with drug-resistant MTLE (NCT05135091).